Drug Addiction Recovery Rates and Long-Term Outcomes

Key Takeaways

• SAMHSA’s 2022 National Survey of Drug Use and Health estimated that approximately 72.2 million Americans (or 75% of those who ever had a substance use problem) consider themselves to be in recovery or to have recovered (SAMHSA, 2023).
• After five years of sustained recovery, the probability of future relapse drops below 15%, according to research from the Recovery Research Institute at Massachusetts General Hospital (Kelly et al., 2019).
• Medication-assisted treatment for opioid use disorder is associated with a 50% reduction in all-cause mortality, per a meta-analysis in The BMJ (Santo et al., 2021).
• Patients who engage in aftercare for at least six months post-treatment are approximately twice as likely to maintain recovery at two years (McKay et al., Journal of Substance Abuse Treatment, 2021).
• Recovery rates are significantly higher when treatment addresses co-occurring mental health conditions alongside substance use (NIDA, 2024).

Statistics updated quarterly. Last reviewed March 28, 2026.

---

Recovery from substance use disorder is not only possible but common. Large-scale survey data indicates that the majority of people who develop a substance use problem eventually achieve recovery, though the timeline and pathway vary widely. This page examines what the data shows about recovery rates, how outcomes differ by treatment type, what predicts long-term success, and where New Jersey-specific data fits within the national picture.

What Recovery Rates Tell Us

Defining Recovery

Recovery has no single clinical definition, which complicates any attempt to report a single recovery “rate.” SAMHSA defines recovery as a process of change through which individuals improve their health and wellness, live self-directed lives, and strive to reach their full potential (SAMHSA, 2012). This definition intentionally encompasses more than abstinence alone.

In clinical research, recovery is typically operationalized in one of several ways:

• Sustained remission: No DSM-5 criteria for substance use disorder met for 12 or more consecutive months.
• Abstinence-based recovery: No use of the primary substance of concern for a defined period (commonly one year or five years).
• Self-identified recovery: The individual considers themselves to be “in recovery,” regardless of clinical assessment. This is the measure used in population-level recovery prevalence surveys.

These different definitions produce different numbers, which is why recovery rate estimates vary across studies and surveys.

National Recovery Prevalence Data

The most comprehensive data on recovery prevalence comes from SAMHSA’s National Recovery Survey, conducted as part of the NSDUH. According to the 2022 survey results, published in 2023:

• Approximately 72.2 million Americans reported that they had resolved a substance use problem, either through treatment, mutual aid, or on their own (SAMHSA, 2023).
• This represents approximately 75% of all individuals who have ever had a substance use problem.
• Among those who identified as being in recovery, approximately 40% reported using formal treatment services, while 60% recovered without formal treatment (though many used informal supports such as 12-step groups, faith communities, or family support).

A separate analysis published in Alcoholism: Clinical and Experimental Research found that among adults who have ever met criteria for alcohol use disorder, approximately 53.9% no longer meet criteria at the time of assessment, with higher recovery rates associated with less severe initial presentations (Dawson et al., 2005; updated estimates in Grant et al., 2015).

These population-level data suggest that recovery is a common outcome, though the path to recovery often involves multiple treatment episodes, periods of relapse, and extended time.

Recovery Rates by Treatment Type

Inpatient vs. Outpatient Outcomes

Treatment outcomes vary by modality, though direct comparisons are complicated by the fact that patients who enter different levels of care typically differ in severity at baseline.

Residential/inpatient treatment: The Drug Abuse Treatment Outcome Studies (DATOS) found that among patients completing residential treatment, approximately 50-60% showed significant improvement in substance use at one-year follow-up, and approximately 25-35% achieved sustained abstinence at five years (Hubbard et al., Drug and Alcohol Dependence, 2003).

Outpatient treatment: DATOS data showed lower abstinence rates for standard outpatient treatment (approximately 20-30% sustained abstinence at one year), though intensive outpatient programs (IOP) produced outcomes approaching those of residential treatment for patients with moderate severity (Simpson et al., Archives of General Psychiatry, 1999).

Long-term residential treatment (therapeutic communities): Patients who completed at least 90 days in a therapeutic community setting showed the highest abstinence rates at follow-up (approximately 40-50% at two years), though these programs also had the highest dropout rates (De Leon et al., Journal of Psychoactive Drugs, 2000).

These findings should not be interpreted as evidence that inpatient treatment is universally superior. Treatment matching, in which patients are assigned to the level of care appropriate for their clinical severity, produces better overall system outcomes than directing all patients to the most intensive level (Moos and Moos, Addiction, 2003).

MAT vs. Abstinence-Based Outcomes

For opioid use disorder, the evidence strongly supports medication-assisted treatment as producing better outcomes than abstinence-only approaches:

• A 2021 meta-analysis published in The BMJ found that MAT with methadone or buprenorphine reduced all-cause mortality by approximately 50% compared to no medication (Santo et al., 2021).
• Retention in treatment, a key predictor of long-term recovery, is substantially higher with MAT. Approximately 60-70% of patients on buprenorphine remain in treatment at six months, compared to 20-30% in non-medication programs (Mattick et al., Cochrane Database of Systematic Reviews, 2014).
• A 2022 study in JAMA Network Open found that patients who received MAT for at least 180 days had a 75% lower risk of fatal overdose in the year following treatment compared to those who did not receive medication (Wakeman et al., 2022).

For alcohol use disorder, FDA-approved medications (naltrexone, acamprosate, disulfiram) improve outcomes modestly when combined with psychosocial treatment. A 2019 meta-analysis in JAMA Internal Medicine found that naltrexone reduced heavy drinking days by approximately 20% compared to placebo (Jonas et al., JAMA, 2014; updated Cochrane review, 2019).

Long-Term Recovery Statistics

The Five-Year Milestone

Research consistently identifies the first five years after achieving initial recovery as the period of highest relapse risk, with risk declining substantially thereafter. Key longitudinal findings include:

• At one year of recovery, the probability of relapse in the following year is approximately 50%, according to research by John Kelly and colleagues at the Recovery Research Institute (Kelly et al., 2019).
• At three years of sustained recovery, the probability of future relapse drops to approximately 25%.
• At five years of sustained recovery, the probability drops below 15%.
• Beyond five years, recovery becomes increasingly stable, with relapse rates comparable to the general population’s risk of developing a new SUD.

These findings come from a longitudinal cohort study published in Alcoholism: Clinical and Experimental Research that followed 1,162 individuals in recovery over an eight-year period (Kelly et al., 2019). The study found that the transition from “early recovery” to “sustained recovery” typically occurs between years three and five.

Predictors of Sustained Recovery

Research has identified several factors that are consistently associated with sustained long-term recovery:

• Engagement in ongoing support: Participation in mutual aid groups (AA, NA, SMART Recovery), outpatient counseling, or recovery coaching is associated with better long-term outcomes. A 2020 Cochrane review found that 12-step facilitation approaches produced abstinence rates comparable to or better than CBT at three-year follow-up (Kelly et al., Cochrane Database of Systematic Reviews, 2020).
• Stable housing: Individuals in stable housing are significantly more likely to maintain recovery. A 2019 study found that housing instability was associated with a 2.5-fold increase in relapse risk (Polcin et al., Journal of Substance Abuse Treatment, 2019).
• Employment or meaningful activity: Employment is associated with improved recovery outcomes, though the direction of causation is bidirectional (Laudet and White, Substance Use and Misuse, 2008).
• Recovery capital: The concept of “recovery capital” encompasses the social, physical, human, and cultural resources available to support recovery. Higher recovery capital at treatment entry predicts better long-term outcomes (Laudet and White, 2008; Granfield and Cloud, 2001).
• Treatment of co-occurring conditions: Addressing mental health conditions alongside substance use disorder significantly improves recovery outcomes. NIDA reports that integrated dual-diagnosis treatment is more effective than treating conditions sequentially (NIDA, 2024).

Recovery Rates in New Jersey

NJ Treatment Outcome Data

New Jersey’s treatment outcome data is limited compared to some states, but available sources provide a partial picture:

• NJ DMHAS reports treatment completion rates for state-funded programs. In fiscal year 2022, approximately 42% of individuals admitted to state-funded treatment completed their treatment episode, while 38% left against clinical advice or were administratively discharged (NJ DMHAS, 2023).
• NJ’s drug court system reports better outcomes: the NJ Administrative Office of the Courts reported that approximately 65% of drug court participants who began the program successfully completed it, and drug court graduates had a 16% recidivism rate at three years compared to 54% for similar individuals processed through the traditional criminal justice system (NJ AOC, 2023).
• The NJ Department of Health tracks overdose survivors and their subsequent treatment engagement. In 2022, approximately 47% of overdose survivors who were connected to treatment at the hospital were still engaged in treatment at 30 days (NJ DOH, 2023).

Access and Its Impact on Recovery

New Jersey’s treatment infrastructure supports recovery through several mechanisms:

• Medicaid coverage of MAT medications and multiple treatment modalities.
• Over 400 licensed treatment facilities across the state, according to SAMHSA’s treatment locator (2024).
• Recovery community organizations in most NJ counties, providing peer support and recovery housing referrals.

However, geographic disparities in treatment access persist. Southern NJ counties with higher overdose rates often have fewer MAT providers per capita than northern NJ counties, a gap that the NJ Department of Health has identified as a priority for state investment (NJ DOH, 2022).

---

This page is part of the Addiction Statistics, Research, and Recovery Data guide on NJ Addiction Centers.

Related resources:

• Rehab Success Rates: What the Data Actually Shows
• What Addiction Has the Highest and Lowest Recovery Rates?
• Stages of Recovery